Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Redx Ready To Get Back To The Clinic After Tough Year

Executive Summary

CEO Lisa Anson has brought "a sense of urgency, focus and realism" to Redx since she took over five months ago, says its chairman, and the firm has high hopes for its investigational porcupine inhibitors.

You may also be interested in...



Redx Raises Funds And Remains Independent

Redx's takeover talks with a consortium led by controversial biotech veteran Sam Waksal, who was jailed for five years over his role in the ImClone stock scandal in 2003, have been terminated but the UK biotech has received a financial lifeline from Redmile and Sofinnova.

Buzz Grows Around Biotech At Former AstraZeneca Campus

Chris Doherty, managing director of the UK's Alderley Park, tells Scrip that the departure of the drug giant from its global R&D headquarters has acted as a catalyst to create a vibrant biotech cluster that is attractive to local, national and international companies.

Monte Rosa Hits The Heights With $96m Cash Hike

The Boston-based biotech has secured a substantial new investment for its protein degradation platform which has the potential to treat currently undruggable cancers in a new way.

Topics

Related Companies

UsernamePublicRestriction

Register

MT142639

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel